Travere to Present New Data on FILSPARI® at ASN Kidney Week
Travere Therapeutics announced it will present nine new data presentations on FILSPARI® (sparsentan) at the American Society of Nephrology (ASN) Kidney Week 2026, including five oral presentations. The data supports FILSPARI®'s role as a foundational treatment for IgA Nephropathy and FSGS.